Risk profile IDs COVID patients who will benefit from baricitinib


MONDAY, Feb. 26, 2024 (HealthDay News) — The Adaptive COVID-19 Treatment Trial (ACTT) risk profile identifies hospitalized COVID-19 patients most likely to respond to baricitinib treatment, according to a study published online Feb. 27. There is benefit. History of Internal Medicine,

Noting that the ACTT risk profile previously demonstrated that hospitalized patients in the high-risk quartile benefit most from remdesivir, Penn State Health Milton S. Kathryn I. Pauls, MD, of Hershey Medical Center, and colleagues investigated potential baricitinib-related treatment effects. By risk quartile in a post hoc analysis of the ACTT-2 trial conducted in 999 adults hospitalized with COVID-19 at 67 trial sites in eight countries. Participants received baricitinib plus remdesivir or placebo plus remdesivir.

The researchers found that baricitinib plus remdesivir reduced the risk of death, progression to invasive mechanical ventilation or death, and improved rates of remission compared with placebo plus remdesivir in high-risk quartiles (hazard ratio, 0.38, 0.57 and 1.53). Was connected. , respectively). Compared with control participants, those receiving baricitinib plus remdesivir had a significantly greater increase in absolute lymphocyte count and a significantly larger decrease in absolute neutrophil count after five days, with the greatest effect seen in the high-risk quartile.

“To our knowledge, no other clinical trial has assessed the clinical benefit from an immunomodulator with respect to dynamics in hematologic parameters, and these data demonstrate the relevance of these measurements in predicting treatment response.” Recommend,” the authors write.

Abstract/full text (may require subscription or payment)

Leave a Comment

“The Untold Story: Yung Miami’s Response to Jimmy Butler’s Advances During an NBA Playoff Game” “Unveiling the Secrets: 15 Astonishing Facts About the PGA Championship”